Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Phase III, Randomized, Observer Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of a Trivalent Subunit Inactivated Flu Vaccine in Healthy Children and Adolescents 3 to 17 Years of Age

NCT01209780 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01209780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01209780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Phase III, Randomized, Observer Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of a Trivalent Subunit Inactivated Flu Vaccine in Healthy Children and Adolescents 3 to 17 Years of Age
Lead sponsor
Novartis Vaccines
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2010
Completion date
September 30, 2011
Enrollment
3,116 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

seasonal influenza